Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00148616
Other study ID # MIND 2
Secondary ID 02T-247 (SMRI)
Status Terminated
Phase Phase 3
First received
Last updated
Start date April 2004
Est. completion date December 2008

Study information

Verified date June 2019
Source Charite University, Berlin, Germany
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of 24 weeks memantine add-on treatment to risperidone for the treatment of negative symptomatology and cognitive impairment in patients with chronic schizophrenia.


Description:

This study examines the efficacy and safety of 24 weeks memantine add-on treatment to risperidone for the treatment of negative symptomatology and cognitive impairment in patients with chronic schizophrenia. The trail was double-blind, prospective, randomized, placebo-controlled, parallel-group and consisting of a 'placebo-run-in' period, treatment, and follow-up periods. Study personnel and participants were blinded to group assignment. In the 'run-in' period, patients received Lorazepam for the treatment of anxiety and tension states for two weeks before starting antipsychotic therapy. After the 'run-in' period treatment, patients began receiving antipsychotic therapy with Risperidon with continuous concomitant administration of a 24 weeks Memantine, 20 mg/d, or placebo. Adherence was assessed at each clinic visit by pill count. In cases of anxiety and tension states, an experienced psychiatrist decided whether patients should receive Lorazepam, 5 mg/d, as rescue medication in addition to the study medication (Memantine or placebo), to which the patients remained blinded. In cases of pseudo parkinsonism patients were allowed to receive Biperiden, up to 8 mg/d, and for the treatment of patients suffering from sleep disorders Zopiclon (15 mg/d) was allowed. The consumption of alcohol and drugs were not allowed during the trial. In both study parts, psychiatric assessments were performed at baseline as well as after 2; 4; 6; 12 and 24 weeks after treatment (that is, during the follow-up period). The neuropsychological examination was performed at baseline, and after 6 and 24 weeks. Psychiatric changes, adverse events, laboratory values, dose adjustments of the antipsychotic therapy, and possible pharmacologic adverse effects were systematically monitored throughout the study.


Recruitment information / eligibility

Status Terminated
Enrollment 13
Est. completion date December 2008
Est. primary completion date June 2008
Accepts healthy volunteers No
Gender All
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria:

- Diagnosis of schizophrenia (DSM-IV)

- Age 18 to 40

- Stable negative syndrome (PANSS negative score > 20)

- At least one previous schizophrenic episode

- Informed consent

- Subjects must be considered by the investigator to be compliant with investigations and appointments

- Subjects must have an educational level and a degree of understanding such that they can meaningfully communicate with the investigator

Exclusion Criteria:

- Axis I disorder other than schizophrenia within 12 months, e.g. schizoaffective disorder

- Severe positive symptomatology (PANNS positive score > PANNS negative score)

- Dependency on alcohol or addictive drugs within 6 months of the baseline evaluation

- Contraindication of risperidone

- Significant neurological, cardiovascular, hepatic, renal, metabolic, or other medical diseases or any clinically relevant abnormalities in laboratory tests

Study Design


Intervention

Drug:
Memantine
Daily dosage of 20 mg Memantine add-on to Risperidone vs. Placebo add-on to Risperidone
Placebos
Daily dosage of 20 mg Placebo add-on to Risperidone vs. Memantine add-on to Risperidone

Locations

Country Name City State
Germany Charité Universitaetsmedizin Berlin; Campus Charité Mitte; Dept. for Psychiatry and Psychotherapy Berlin

Sponsors (2)

Lead Sponsor Collaborator
M. Schaefer, MD Stanley Medical Research Institute

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in PANSS negative subscore between memantine and placebo treatment during trial
See also
  Status Clinical Trial Phase
Completed NCT00161044 - An Open-Label Investigation of the Adjuvant Therapeutic Effects of Galantamine in Patients With Chronic Schizophrenia and Persistent Deficit Symptoms N/A
Completed NCT01450514 - POC Study of Pipamperone Added to Stable Treatment With RIS or PAL in Chronic Schizophrenia Phase 2
Completed NCT05809882 - Study of Experience of High-frequency Repetitive Transcranial N/A
Recruiting NCT05948696 - Experience of Horticultural Group Therapy Among People With Chronic Schizophrenia
Completed NCT06206798 - Resourcefulness Group Intervention on Recovery and Quality of Life N/A
Completed NCT01761383 - Role of Nintendo Wii in Improving Negative Symptoms and Quality of Life in Chronic Schizophrenia N/A
Completed NCT01891929 - Cognitive Remediation and Sheltered Employment in Schizophrenia N/A
Completed NCT03275909 - Integrated Psychological Therapy for Chronic Schizophrenia N/A
Completed NCT02298985 - Curcumin Addition to Antipsychotic Treatment in Chronic Schizophrenia Patients Phase 4
Recruiting NCT00525863 - Oxygen Therapy in Schizophrenia Phase 3
Completed NCT02624167 - A Study to Determine the Safety, Tolerability and Efficacy NW-3509A in Patients With Chronic Schizophrenia Phase 2
Completed NCT00789698 - Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic Schizophrenia Phase 3
Recruiting NCT06349369 - Effect of tDCS on Inflammatory Biomarkers in Chronic Schizophrenia N/A
Completed NCT02421146 - The Effect of Transcranial Direct Current Stimulation on Human Brains: A Neuroimaging Study N/A
Active, not recruiting NCT00664274 - Relation of Catechol-O-methyltransferase (COMT) Genotype and Response to Cognitive Remediation Schizophrenia N/A